Evidence map›Paper›PMID 33047474›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2021

Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

Adam P Mecca, Christopher H van Dyck

Abstract readLetterComment
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Rare mixed dementia: A case report.World journal of radiology · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Adam P MeccaAlzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, USA.
Christopher H van DyckAlzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER · 2020 to 2026
$30.2M
Prion Protein in Alzheimer's Disease PathophysiologyR01AG034924 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER · 2010 to 2026
$9.6M
PET Imaging of SV2A and Other Biomarkers in Alzheimer's DiseaseR01AG062276 · NIA · YALE UNIVERSITY · PI VAN DYCK, CHRISTOPHER H · 2018 to 2022
$5.5M
Investigation of molecular changes in mGluR5 and SV2A to study synaptic alterations in Alzheimer's disease using PET.K23AG057794 · NIA · YALE UNIVERSITY · PI MECCA, ADAM PETER · 2018 to 2022
$977k
NCATS NIH HHS UL1 TR001863NIA NIH HHS K23 AG057794NIA NIH HHS P30 AG066508NIA NIH HHS R01 AG062276
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseDementiaHumansMembrane GlycoproteinsNerve Tissue ProteinsPositron-Emission TomographyRisk FactorsMembrane GlycoproteinsNerve Tissue ProteinsSV2A protein, human

Identifiers

PMID33047474
PMCPMC7962853

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.